- Home
- SKYH vs BBIO Comparison
SKYH vs BBIO Comparison
Compare SKYH & BBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SKYH
- BBIO
- Stock Information
- Founded
- SKYH 2017
- BBIO 2015
- Country
- SKYH United States
- BBIO United States
- Employees
- SKYH N/A
- BBIO N/A
- Industry
- SKYH Military/Government/Technical
- BBIO Biotechnology: Pharmaceutical Preparations
- Sector
- SKYH Industrials
- BBIO Health Care
- Exchange
- SKYH Nasdaq
- BBIO Nasdaq
- Market Cap
- SKYH 325.2M
- BBIO 8.0B
- IPO Year
- SKYH N/A
- BBIO 2019
- Fundamental
- Price
- SKYH $10.05
- BBIO $46.47
- Analyst Decision
- SKYH Strong Buy
- BBIO Strong Buy
- Analyst Count
- SKYH 3
- BBIO 14
- Target Price
- SKYH $14.83
- BBIO $60.21
- AVG Volume (30 Days)
- SKYH 167.7K
- BBIO 3.3M
- Earning Date
- SKYH 08-12-2025
- BBIO 07-31-2025
- Dividend Yield
- SKYH N/A
- BBIO N/A
- EPS Growth
- SKYH N/A
- BBIO N/A
- EPS
- SKYH N/A
- BBIO N/A
- Revenue
- SKYH $17,950,000.00
- BBIO $127,415,000.00
- Revenue This Year
- SKYH $122.85
- BBIO $107.34
- Revenue Next Year
- SKYH $45.30
- BBIO $49.48
- P/E Ratio
- SKYH N/A
- BBIO N/A
- Revenue Growth
- SKYH 102.32
- BBIO N/A
- 52 Week Low
- SKYH $8.26
- BBIO $21.72
- 52 Week High
- SKYH $14.52
- BBIO $46.80
- Technical
- Relative Strength Index (RSI)
- SKYH 50.36
- BBIO 71.64
- Support Level
- SKYH $9.75
- BBIO $41.80
- Resistance Level
- SKYH $10.56
- BBIO $46.80
- Average True Range (ATR)
- SKYH 0.28
- BBIO 1.44
- MACD
- SKYH 0.10
- BBIO 0.09
- Stochastic Oscillator
- SKYH 60.16
- BBIO 94.00
About SKYH Sky Harbour Group Corporation
Sky Harbour Group Corp is an aviation infrastructure company building a nationwide network of Home-based solutions for business aircraft. The company develops, leases, and manages business aviation hangars across the United States based on its proprietary targeting and acquisition model, targeting airfields with hangar supply and demand imbalances in the markets. Its hangar campuses feature exclusive private hangars and a full suite of dedicated services specifically designed for home-based aircraft.
About BBIO BridgeBio Pharma Inc.
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis) , is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.